Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00114920
Recruitment Status : Completed
First Posted : June 21, 2005
Last Update Posted : February 19, 2007
Information provided by:
Graceway Pharmaceuticals, LLC

Brief Summary:

The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks.

A second purpose is to evaluate the safety of the drug.

Condition or disease Intervention/treatment Phase
Warts Drug: Resiquimod Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 88 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel for the Treatment of Common Warts in Adults
Study Start Date : March 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Warts

Primary Outcome Measures :
  1. Clearance of treated common wart(s)

Secondary Outcome Measures :
  1. Partial clearance of treated common wart(s)
  2. Wart recurrence

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of common warts
  • Two forms of birth control

Exclusion Criteria:

  • Pregnant or breast feeding
  • Other types of wart(s), ie. plantar
  • Currently participating in another clinical study
  • Chronic viral hepatitis B or C

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00114920

United States, Indiana
Welborn Clinic
Evansville, Indiana, United States, 47713
Sponsors and Collaborators
Graceway Pharmaceuticals, LLC Identifier: NCT00114920     History of Changes
Other Study ID Numbers: 1508-RESI
First Posted: June 21, 2005    Key Record Dates
Last Update Posted: February 19, 2007
Last Verified: November 2006

Keywords provided by Graceway Pharmaceuticals, LLC:
Common Wart(s)

Additional relevant MeSH terms:
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases